Tango Therapeutics
TNGX
247 hedge funds and large institutions have $6.6B invested in Tango Therapeutics in 2026 Q2 according to their latest regulatory filings, with 78 funds opening new positions, 102 increasing their positions, 55 reducing their positions, and 22 closing their positions.
255% more first-time investments, than exits
New positions opened: 78 | Existing positions closed: 22
85% more repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 55
75% more capital invested
Capital invested by funds: $3.77B → $6.6B (+$2.83B)
70% more call options, than puts
Call options by funds: $11.2M | Put options by funds: $6.59M
36% more funds holding in top 10
Funds holding in top 10: 14 → 19 (+5)
27% more funds holding
Funds holding: 194 → 247 (+53)
21.5% more ownership
Funds ownership: 126.33% → 147.82% (+21%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$135M |
| 2 |
Goldman Sachs
New York
|
+$121M |
| 3 |
BlackRock
New York
|
+$91.2M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$78.6M |
| 5 |
SFCM
Seven Fleet Capital Management
Mountain View,
California
|
+$67.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$178M |
| 2 |
NI
Nextech Invest
Zurich,
Switzerland
|
-$152M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$98.9M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$44.8M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$42.2M |
TNGX Hedge Fund Activity: Q2 2026 in Review
247 institutional investors reported a position in Tango Therapeutics (TNGX) for Q2 2026, worth a combined $6.6B — up 75% from $3.77B a quarter earlier.
Buyers outnumbered sellers: 78 funds opened new TNGX positions and 22 closed out — a net gain of 56 holders — while 102 added to existing stakes and 55 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $135M. The largest seller was Adage Capital Partners, cutting an estimated $178M.
- 247 institutional investors held Tango Therapeutics (TNGX) as of Q2 2026, up from 194 in Q1 2026.
- Funds reported $6.6B of Tango Therapeutics stock for Q2 2026, up 75% quarter-over-quarter.
- 78 funds opened new Tango Therapeutics positions in Q2 2026 and 22 closed out, a net change of +56 holders.
- The largest Tango Therapeutics buyer in Q2 2026 was T. Rowe Price Associates, an estimated $135M added.
- The largest Tango Therapeutics seller in Q2 2026 was Adage Capital Partners, an estimated $178M sold.
Based on aggregated 13F filings for Q2 2026.